Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.
In this study, researchers are comparing the effectiveness bevacizumab plus osimertinib versus osimertinib alone as initial treatment for patients with stage IIIB-IV non-small cell lung cancer that contains a mutation in a gene called EGFR.
After endometrial cancer surgery, there is a risk that the cancer will come back. Combining a shorter course of radiation treatment with chemotherapy may decrease the chance of endometrial cancer recurring.
Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.
Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.
Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:
The purpose of this study is to assess the safety and effectiveness of the investigational drug MORAb-202 in people with endometrial or ovarian cancer. MORAb-202 targets a protein called FRA on cancer cells and delivers eribulin (a chemotherapy drug) directly to these cells, which may slow or stop cancer growth. MORAb-202 is given intravenously (by vein).
Patients receiving certain drugs for breast cancer, such as doxorubicin or trastuzumab, may experience impaired heart function. Researchers at Memorial Sloan Kettering Cancer Center are conducting a study to see if it is possible to grow heart muscle cells ("cardiomyocytes") from blood or skin cells from breast cancer patients. The skin cells will be grown in a special mixture in the laboratory designed to transform them from skin cells into heart muscle cells.
Researchers want to see if ASTX727 is practical and safe for people with high-risk clonal cytopenia of undetermined significance (CCUS). With CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells. CCUS can lead to precancerous conditions such as myelodysplastic syndrome or blood cancers such as acute myeloid leukemia.
